Try our beta test site
1 study found for:    Ghielmini Waldenstrom's
Show Display Options
Rank Status Study
1 Completed Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Condition: Lymphoma
Interventions: Drug: ibritumomab tiuxetan;   Drug: rituximab;   Drug: melphalan;   Drug: vinorelbine tartrate / G-CSF;   Procedure: autologous hematopoietic stem cell harvesting and transplantation

Study has passed its completion date and status has not been verified in more than two years.